Interferon beta-1a
- Generic Name
- Interferon beta-1a
- Brand Names
- Avonex, Rebif
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 145258-61-3
- Unique Ingredient Identifier
- XRO4566Q4R
- Background
Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
- Indication
For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum
- Associated Conditions
- Relapsing Multiple Sclerosis (RMS)
- Associated Therapies
- -
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2024-05-16
- Target Recruit Count
- 57
- Registration Number
- NCT06019130
- Locations
- 🇩🇪
Department of Pediatric Oncology and Hematology, Charité University Medicine Berlin, Berlin, Germany
🇩🇪Uniklinik RWTH Aachen, Department of Internal Medicine, Aachen, Germany
🇩🇪Evangelisches Klinikum Bethel, Children's Hospital, Bielefeld, Germany
Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients
- Conditions
- Interventions
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- German University in Cairo
- Target Recruit Count
- 80
- Registration Number
- NCT05298670
- Locations
- 🇪🇬
Nasser Institute for Research and Treatment, Cairo, Egypt
Public Health Emergency: SOLIDARITY TRIAL Philippines
- Conditions
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- University of the Philippines
- Target Recruit Count
- 1314
- Registration Number
- NCT05024006
- Locations
- 🇵ðŸ‡
Chinese General Hospital, Manila, Metro Manila, Philippines
🇵ðŸ‡UP - Philippine General Hospital, Manila, Metro Manila, Philippines
🇵ðŸ‡San Juan de Dios Educational Foundation Inc - Hospital, Pasay, Metro Manila, Philippines
Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19
- Conditions
- Interventions
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Synairgen Research Ltd.
- Target Recruit Count
- 623
- Registration Number
- NCT04732949
- Locations
- 🇧🇷
Instituto Mederi de Pesquisa e Saúde, Passo Fundo, Rio Grande Do Sul, Brazil
🇲🇽Hospital General de Culiacan D, Culiacan, Sinaloa, Mexico
🇲🇽Hospital General Regional O´Hu, Merida, Yucatán, Mexico
World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments
- Conditions
- Interventions
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- The University of The West Indies
- Target Recruit Count
- 100
- Registration Number
- NCT04647669
- Locations
- 🇯🇲
Univeristy of the West Indies, Kingston, Jamaica
ACTIV-2: A Study for Outpatients With COVID-19
- Conditions
- Interventions
- Biological: bamlanivimab 7000mgDrug: Placebo for Bamlanivimab 7000mgBiological: bamlanivimab 700mgDrug: Placebo for Bamlanivimab 700mgBiological: BRII-196+BRII-198Drug: Placebo for BRII-196+BRII-198Biological: AZD7442 (IV)Drug: Placebo for AZD7442 (IV)Biological: AZD7442 (IM)Drug: Placebo for AZD7442 (IM)Drug: Placebo for SNG001Drug: Placebo for CamostatBiological: SAB-185 (3,840 Units/kg)Drug: Placebo for SAB-185 (low dose)Drug: CASIRIVIMAB + IMDEVIMABBiological: SAB-185 (10,240 Units/kg)Drug: Placebo for SAB-185 (high dose)Biological: BMS-986414 + BMS-986413Drug: Placebo for BMS-986414 + BMS-986413Drug: SNG001Drug: Camostat
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2024-08-02
- Target Recruit Count
- 4044
- Registration Number
- NCT04518410
- Locations
- 🇺🇸
Rare Disease Research, LLC. (Site 1248), 1891 Howell Mill Rd.NW, Ste. B, Atlanta, Georgia, United States
🇺🇸Baltimore VA Medical Center (Site 1258), 10 N. Greene St., Baltimore, Maryland, United States
🇺🇸Johns Hopkins University (Site 1006), 1830 East Monument Street, Baltimore, Maryland, United States
Adaptive COVID-19 Treatment Trial 3 (ACTT-3)
- Conditions
- Interventions
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2022-03-14
- Target Recruit Count
- 969
- Registration Number
- NCT04492475
- Locations
- 🇺🇸
Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States
🇺🇸University of Illinois at Chicago Division of Infectious Diseases, Chicago, Illinois, United States
🇺🇸University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States
Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Qassim University
- Target Recruit Count
- 200
- Registration Number
- NCT04460547
Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Synairgen Research Ltd.
- Target Recruit Count
- 221
- Registration Number
- NCT04385095
- Locations
- 🇬🇧
Hull and East Yorkshire NHS Trust, Castle Hill Hospital,, Hull, United Kingdom
🇬🇧City Campus of Nottingham University, Nottingham, United Kingdom
🇬🇧Belfast City Hospital, Belfast, United Kingdom
Interferon Beta 1a in Hospitalized COVID-19 Patients
- Conditions
- Interventions
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT04350671
- Locations
- 🇮🇷
Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.